MARATTO

article · Bulletin de la Dialyse à Domicile

Artificial Intelligence for Home Dialysis: An Innovative Response to the Challenges of Chronic Kidney Disease in the Caribbean-Guyana.

Abstract

Chronic kidney disease (CKD) represents a major global public health challenge, affecting nearly 850 million people and ranking among the fastest-growing causes of premature mortality. In the French West Indies and Guiana region, end-stage renal disease (ESRD) places a disproportionate burden on healthcare systems, exacerbated by low medical density, geographic dispersion, and cultural diversity. Home dialysis, including peritoneal dialysis and hemodialysis, is an essential tool that improves quality of life, autonomy, and continuity of care. However, its adoption remains limited due to human, organizational, and medical barriers. Artificial intelligence (AI) emerges as a strategic lever to overcome these limitations, enabling the prediction of complications, personalized treatment optimization, and proactive telemonitoring. Its implementation requires careful attention to ethical issues, data protection, professional training, and adaptation to local cultural contexts. International experiences demonstrate that such approaches improve safety, adherence, and technical survival. In overseas territories, AI can transform home dialysis into a scalable, equitable, and sustainable solution, addressing both healthcare challenges and organizational constraints, while placing the patient and their cultural context at the heart of care management.

Research topics

  • Dialysis and Renal Disease Management
  • Artificial Intelligence in Healthcare and Education
  • Artificial Intelligence in Healthcare

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.25796/bdd.v8i4.87091

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.